[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital de Clinicas José de San Martín\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":149},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,74,98,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100642003","transition-from-sevoflurane-to-total-intravenous-anesthesia-in-pediatric-patients-100642003",false,"NCT07644260","Transition From Sevoflurane to Total Intravenous Anesthesia in Pediatric Patients","Observational Analysis of the Transition From Inhalational Anesthesia to Total Intravenous Anesthesia Guided by Bispectral Index and the Eleveld Model in Pediatric Patients","TSTP","Inclusion Criteria:\n\n* Age 2 to 12 years\n* Scheduled for elective low- or intermediate-risk surgery according to the National Institute for Health and Care Excellence (NICE) surgical risk stratification (e.g., tonsillectomy, adenoidectomy, postioplasty, orchidectomy, orchidopexy, inguinal herniorrhaphy)\n* American Society of Anesthesiologists (ASA) Physical Status Classification I or II\n\nExclusion Criteria:\n\n* Refusal of parents\u002Flegal guardians to sign informed consent, or refusal of the child to provide assent when applicable\n* Cardiovascular or neurological disease that may interfere with anesthesia or with the pharmacokinetic model\n* History of allergy or adverse reaction to inhalational or intravenous anesthetic agents used in the protocol\n* Airway malformations or conditions that complicate standard intubation or airway management\n* Psychological or neurological conditions requiring sedative or hypnotic premedication prior to the anesthetic procedure\n* Treatment with drugs that may alter the pharmacokinetics or pharmacodynamics of the anesthetic agents\n* Difficult peripheral venous access","ALL","2 Years","12 Years",{"count":21,"type":22},50,"ESTIMATED","1 Day","OBSERVATIONAL","his prospective, observational, exploratory, and multicenter study aims to describe the evolution of propofol effect-site concentration administered via target-controlled infusion (TCI) based on the Eleveld model-with adjustments for opioid co-administration-guided by the bispectral index (BIS) during the transition from inhalational anesthesia with sevoflurane to total intravenous anesthesia (TIVA) in pediatric patients.The study population will include 50 pediatric patients, aged 2 to 12 years, scheduled for elective low- or medium-complexity surgeries. Induction will be performed with sevoflurane, followed by intravenous access placement and transition to TIVA using propofol and remifentanil via TCI. As part of the neuromonitoring, the bispectral index, spectral edge frequency (SEF), and median frequency (MF) will be recorded. Additionally, hemodynamic parameters will be recorded on a minute-by-minute basis.The primary objective is to describe BIS-guided adjustments of propofol during the anesthetic transition. Secondary objectives include describing interindividual variability in propofol titration, time to reach a BIS of 40-60, burst suppression patterns, SEF, MF, drug consumption, hemodynamic stability, and clinical adverse events. Statistical analysis will be primarily descriptive, examining correlations between BIS, propofol, and the minimum alveolar concentration (MAC) of sevoflurane.",[27,28,29],"Anesthesia","Pediatric Anesthesia","Total Intravenous Anesthesia",[29,31,32,33,34,35,36,37,38,28,39],"TIVA","Bispectral Index","BIS","Propofol","Sevoflurane","Eleveld","Target-Controlled Infusion","TCI","Anesthesia Transition","NOT_YET_RECRUITING","2026-06-08",{"date":43,"type":44},"2026-06-12","ACTUAL",{"date":46,"type":22},"2026-05-26",{"date":48,"type":22},"2027-03-28",{"name":50,"class":51},"Hospital de Clinicas José de San Martín","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100608776","automatic-detection-of-dyspnea-in-mechanically-ventilated-critically-ill-patients-100608776","NCT07205952","Automatic Detection of Dyspnea in Mechanically Ventilated, Critically Ill Patients","Inclusion criteria:\n\n* Adults of either sex (≥18 years)\n* Endotracheally intubated in the past 24 hours.\n* Expected to require ≥24 hours of mechanical ventilation.\n\nExclusion criteria:\n\n* Continuous neuromuscular blockade.\n* Ventilated on Airway Pressure Release Ventilation mode.",{"count":60,"type":22},60,"The investigators will conduct a prospective, observational, two-center ICU study of 60 subjects on mechanical ventilation with respiratory failure of any cause.",[63],"Dyspnea During Mechanical Ventilation","RECRUITING","2025-09-25",{"date":67,"type":44},"2025-10-03",{"date":69,"type":44},"2024-11-22",{"date":71,"type":22},"2025-10",{"name":50,"class":51},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":73},"100542202","role-of-mucosal-impedance-measurement-for-the-diagnosis-of-gastroesophageal-reflux-disease-100542202","NCT06339801","Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Patients \\>18 years presenting symptoms of GERD that have not adequately responded to proton pump inhibitors (PPIs) treatment after 8 weeks and have undergone upper gastrointestinal endoscopy (UGIE) without erosive esophagitis.\n\nPatients with a broad spectrum of severity, assessed through the GERDq score, will be included\n\nExclusion Criteria:\n\n* ● Pregnancy or lactation\n\n  * Esophageal disorders (esophageal motor disorders, eosinophilic esophagitis, neoplastic diseases)\n  * Uncontrolled systemic diseases (diabetes mellitus, hypo- or hyperthyroidism, cancer, etc.)\n  * Lack of informed consent\n  * Severe psychiatric disorders","18 Years","65 Years",{"count":83,"type":22},100,"Existing current tests for diagnosing GERD are suboptimal because they lack adequate sensitivity or specificity. Upper gastrointestinal endoscopy is highly specific for diagnosing GERD, particularly when erosive esophagitis is present (Los Angeles Classification B, C, or D). Nevertheless, its sensitivity is limited, as this scenario is only present in 30% of cases. Most patients will exhibit normal endoscopic findings, indicating Non-Erosive Reflux Disease (NERD). The 24-hour impedance-pH monitoring (MII) is currently considered the gold standard. However, its main limitation is that it can only measure reflux activity over a 24-hour period, in addition to the discomfort caused by the catheter. 6-8 It is noteworthy that 50% of patients with NERD will have pathological reflux, and the other 50% will have a sensory disorder. The importance of making an accurate diagnosis lies in the treatment, which varies in each case.11 Recently, a minimally invasive device was developed and validated in the USA to assess changes in esophageal mucosal impedance. This serves as a tool for evaluating tissue changes associated with chronic reflux. However, this device has recently undergone improvements. This new technology has not been tested yet for GERD diagnosis. The primary benefit would be the ability to diagnose GERD in symptomatic patients with NERD during the initial endoscopy conducted under sedation.\n\nObjectives\n\nThe Main objectives of this study are to:\n\n1. Evaluate the diagnostic performance of mucosal impedance measurement.\n2. Investigate the mucosal impedance pattern in patients with and without GERD.\n\nSecondary objectives:\n\n1. Evaluate the correlation between the global mucosal impedance measurement vs the first 3cm measurement\n2. Evaluate the best probability score to distinguish between GERD and non-GERD Design Prospective, cross-sectional, and analytical study Study Design and Procedures The study will be conducted in the Gastroenterology Department of the Hospital de Clínicas José de San Martin, University of Buenos Aires, Argentina. Following a 4-week screening period during which a proton pump inhibitor (PPI) washout will be performed, and baseline measurements will be taken, all patients will undergo upper gastrointestinal endoscopy with mucosal impedance measurement and 24-hour impedance\u002FpH monitoring.",[86],"Gastroesophageal Reflux",[88,89],"gastroesophageal reflux","mucosal impedance","2025-01-01",{"date":92,"type":44},"2025-01-03",{"date":94,"type":44},"2024-12-12",{"date":96,"type":22},"2026-08-01",{"name":50,"class":51},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":73},"100559260","body-composition-estimated-by-bioelectrical-impedance-analysis-in-patients-with-acute-coronary-syndrome-100559260","NCT06561815","Body Composition Estimated by Bioelectrical Impedance Analysis in Patients with Acute Coronary Syndrome.","Inclusion Criteria: All patients hospitalized in the Cardiovascular Care Unit with a diagnosis of acute coronary syndrome.\n\nExclusion Criteria: Decline to participate.",{"count":83,"type":22},"This study addresses the critical issue of obesity and its impact on patients with acute coronary syndrome (ACS). While obesity is a known risk factor for cardiovascular diseases, emerging evidence suggests that obese patients with coronary artery disease may have better survival outcomes-a phenomenon known as the \\"obesity paradox.\\"\n\nOur research aims to explore this paradox by examining the body composition of ACS patients using bioimpedance analysis (BIA). We will evaluate parameters such as lean mass, body fat, and fluid volume to assess their relationship with clinical outcomes, including mortality and the incidence of heart and kidney failure.\n\nBy focusing on body composition rather than just BMI, this study seeks to provide a more accurate understanding of how these factors influence patient outcomes. Conducted at a major hospital in Argentina, the study will contribute valuable insights into the role of body composition in the prognosis of ACS, potentially informing more personalized treatment strategies.",[107,108],"Coronary Syndrome","Obesity",[110,111,112],"Obesity Paradox","Acute Coronary Syndrome","Body Composition","2024-08-15",{"date":115,"type":44},"2024-08-20",{"date":117,"type":44},"2023-02-11",{"date":119,"type":22},"2025-11-30",{"name":50,"class":51},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":73},"100555555","cellular-immunity-neuroendocrine-and-inflammatory-factors-for-clinical-prognosis-in-acute-coronary-syndrome-100555555","NCT06513611","Cellular Immunity, Neuroendocrine, and Inflammatory Factors for Clinical Prognosis in Acute Coronary Syndrome","Identificación de la relación Entre Componentes de la Inmunidad Celular y Factores Inflamatorios y neuroendócrinos Como Determinantes Del pronóstico clínico en el síndrome Coronario Agudo","Inclusion Criteria:\n\n* Are over 21 years of age and admitted to the Coronary Unit of the Hospital de Clínicas with a diagnosis of Acute Coronary Syndrome (ACS).\n* Agree to participate in the study through informed consent.\n\nExclusion Criteria:\n\n* Concomitant diagnosis of chronic neoplastic or inflammatory disease.\n* Diagnosis of allergic disease, parasitic disease, asthma, or hypereosinophilic syndrome.\n* Severe associated valvular disease.\n* Acute myocardial infarction (AMI) in the previous month.\n* Chronic corticosteroid treatment.\n* Creatinine clearance \\\u003C30% by MDRD (Modification of Diet in Renal Disease).\n* Severe hepatic insufficiency.\n* Pregnant women.\n* Known disease that limits their life expectancy to 6 months.\n* Refuse to participate in the study either by their own will or unable to understand its characteristics due to their clinical condition.","21 Years",{"count":130,"type":22},150,"In acute coronary syndrome (ACS), there is an increase in cortisol levels, as an expression of the stress response, and C-reactive protein, as an expression of the inflammatory response, which are in turn associated with changes in the components of cellular immunity, and ultimately are predictors of clinical events. The objective of this study is to demonstrate that, within the frame of reference of ACS, beyond the thrombotic phenomenon that leads to ischemia and myocardial necrosis, there is an activation of an inflammatory and stress response, evidenced by an elevation of CRP and cortisol, respectively, and sequentially modifications in the components of cellular immunity in peripheral blood that convey prognostic value during hospitalization and after discharge. A prospective, observational, analytical, unicentric study of consecutive patients with ACS, with telephone follow-up to 6 months, will be carried out. For 2 years, all eligible patients admitted with a diagnosis of ACS to the Coronary Care Unit of the Hospital de Clínicas José de San Martín in Buenos Aires will be registered consecutively.",[111,133,134,135,136],"Stress Hyperglycemia","Cortisol; Hypersecretion","Inflammatory Response","Coagulation",[138,139,140],"acute coronary syndrome","inflammation","cellular immunity","2024-07-16",{"date":143,"type":44},"2024-07-22",{"date":145,"type":44},"2024-01-01",{"date":147,"type":22},"2026-07-01",{"name":50,"class":51},""]